|
|
Visiting Faculty
CP3 is thrilled to announce its first Visiting Scholar, Dan Hartung, PharmD, MPH. Dr. Hartung is Professor of Pharmacy in the Oregon State University College of Pharmacy. Dr. Hartung is a pharmaceutical health services researcher who’s work involves studying state, payer, and health system policies to reduce risks and improve outcomes for individuals with substance use disorders. Dr. Hartung also conducts research to examine the reasons for, and consequences of, the high cost of disease-modifying therapy for multiple sclerosis.
Dr. Hartung will join us on the Pitt campus April 1 – June 30, 2024. While here, he will work with CP3 faculty to analyze uptake and price of new high-cost prescription drugs recently on the market. He will also be a panelist at the CP3’s 3rd Annual Pharmacoequity Conference on May 3, 2024. We look forward to Dr. Hartung’s time in Pittsburgh!
|
|
|
|
Our Pharmacoequity Conference planning committee has been hard at work the past few months, and we are thrilled to announce that registration is open for our 3rd Annual Pharmacoequity Conference! The conference takes place on May 3 from 8 AM – 2 PM at the University Club on the University of Pittsburgh campus; we have a virtual option available for those that are unable to join us in person.
This year, we welcome keynote speaker Dr. Fumiko Chino from Memorial Sloan Kettering Cancer Center, whose address “Financial Toxicity in America” is sure to be powerful.
Funding for this conference was made possible in part by grant 1R13HS030049-01 from the Agency for Healthcare Research and Quality (AHRQ). We are also grateful to Arnold Ventures and the University of Pittsburgh School of Pharmacy for their continued sponsorship and support of this conference.
More information and a registration link are available here. We hope to see you on May 3!
|
|
|
|
|
|
Congratulations to Assistant Professor of Medicine and CP3 Faculty Affiliate Dr. Tim Anderson for being named an Associate Editor of JAMA Internal Medicine!
Congratulations are also in order for Associate Professor of Pharmacy Dr. Lucas Berenbrok for being elected as a fellow of the American Pharmacists Association (APhA) by its Academy of Pharmacy Practice and Management. Dr. Berenbrok, also a CP3 Faculty Affiliate, was only one of 10 selected for the honor for professional practice and service achievements.
|
|
|
|
|
The HumAn-1 Trial, led at Pitt by Dr. Jing Luo, recently reached a huge milestone. They’ve reached 100% of their recruitment goal for their study sites in Tanzania! This international clinical trial is the first of its kind to generate high quality evidence on the use of analogue insulins and feasibility of using continuous glucose monitors in less resourced settings for young people with Type 1 Diabetes. Study staff in Tanzania and Bangladesh have enrolled 400 participants overall.The above photo was taken by BIRDEM research assistant Nowroj Kabir Prottoy when traveling to complete a home visit near the Bay of Bengal
Dr. Katie Suda was awarded a Diversity Supplement for her NIH R01 on improving patient safety in pediatric dentistry. This supplement is led by Dr. Nancy Gauvin in the School of Health and Rehabilitation Sciences and aims to improve health care for children in underrepresented populations who have been diagnosed with a resonance disorder of hypernasality.
The mPROVEN study, led by Dr. Walid Gellad, has completed usability testing for its EHR-based alerts for primary care patients at elevated overdose risk. The study team is looking toward a 2025 start for the start of a large cluster randomized trial of a machine-learning prediction algorithm paired with targeted EHR provider interventions to reduce overdose among primary care patients.
|
|
Selected Recently Published Papers
Older Adult and Primary Care Practitioner Perspectives on Using, Prescribing, and Deprescribing Opioids for Chronic Pain
Timothy S. Anderson, MD, MAS; Brianna X. Wang, BS; Julia H. Lindenberg, MD; Shoshana J. Herzig, MD, MPH; Dylan M. Berens, MS; Mara A. Schonberg, MD, MPH
JAMA Network Open, March 6, 2024
Racial and Ethnic Disparities in Geographic Availability of Buprenorphine
Drake, Coleman PhD; Nagy, Dylan MS; Meiselbach, Mark K. PhD; Zhu, Jane M. MD, MPP; Saloner, Brendan PhD; Stein, Bradley D. MD, PhD; Polsky, Daniel PhD
Journal of Addiction Medicine, February 20, 2024
Prevalence of unnecessary antibiotic prescriptions among dental visits, 2019
Ashlee M. Murphy, Ursula C. Patel, Geneva M. Wilson, Katie J. Suda
Infection Control & Hospital Epidemiology, January 20, 2024
Trends in Phenylephrine and Pseudoephedrine Sales in the US
Timothy S. Anderson, MD, MAS; Katie J. Suda, PharmD, MS; Walid F. Gellad, MD, MPH; Mina Tadrous, PharmD, PhD
JAMA, February 8, 2024
Early Mortality After the First Dose of Coronavirus Disease 2019 Vaccination: A Target Trial Emulation
Kevin W McConeghy, Kwan Hur, Issa J Dahabreh, Rong Jiang, Lucy Pandey, Walid F Gellad, Peter Glassman, Chester B Good, Donald R Miller, Andrew R Zullo, Stefan Gravenstein, Francesca Cunningham
Clinical Infectious Diseases, February 6, 2024
Differences in Primary Care Follow-up After Acute Care Discharge Within and Across Health Systems: a Retrospective Cohort Study
Timothy S Anderson, Ashley L O'Donoghue, Shoshana J Herzig, Marc L Cohen, Naing Aung, Tenzin Dechen, Bruce E Landon, Jennifer P Stevens
Journal of General Internal Medicine, January 16, 2024
|
|
|
|
Dr. Walid Gellad spoke with The Washington Post about the CDC's changes to Covid isolation guidelines. He recommended weighing risks of immunocompromised people with risks of missing work/school. “It really is a different world now,” he said.
Dr. Katie Suda and colleagues discussed antimicrobial stewardship in dentistry and their recent work on the topic on Episode 43 of The ICHE Podcast.
Dr. Tim Anderson appeared on NPR's Morning Edition discussing his new paper describing low statin use among people who are eligible to take them. "What's surprising here is that it's fully leveled off, and that has even happened as statins have become more affordable. And so that leveling off is quite surprising," he said. Listen to the interview here.
|
|
|
|
We’re looking forward to sharing our suite of risk prediction projects with attendees of the Rx & Illicit Drug Summit in Atlanta in April 2024. Drs. Gellad and Lo-Ciganic will present how our team uses advanced predictive analytics to develop models predicting overdose, and how we work with stakeholders to refine and implement the models into practice.
|
|
Registration is open for the 3rd Annual Pharmacoequity Conference! Join us in Pittsburgh on May 3, or virtually wherever you are!
|
|
|
 |
|
